GEN Exclusives

More »

GEN News Highlights

More »
Jan 28, 2011

Orion and Endo Establish Cancer Drug Alliance

  • Endo Pharmaceuticals and Orion have established a collaboration to discover, develop, and commercialize new cancer drugs originating from both their discovery-stage pipelines. The partnership will focus on four of each firms’ candidates. Under terms of the deal all development costs will be shared, with Orion retaining marketing rights to resulting drugs in Europe (including Russia), and Endo retaining marketing rights in North America.

    They will jointly decide on the best commercialization strategies for other countries, after Phase II development. In addition, both companies will be able to exclusively license each others’ development-ready programs at predetermined stages, and share development costs.

    Finland-based Orion says the partnership will immediately extend both firms’ oncology pipeline. “The agreement is also perfectly in line with Orion’s R&D strategy to focus on risk-sharing partnerships,” remarks Reijo Salonen, Ph.D., svp for R&D at Orion. “This alliance marks another milestone in the transformation of Endo’s R&D platform,” adds Ivan Gergel, M.D., executive vp for R&D at Endo. “This type of collaboration fits well into our new, efficient, and effective virtual R&D model.”



Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »